John Cook

2 papers in the library · publishing 2022-2023

Papers

Sort Most recent Most cited

The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?

Advances in experimental medicine and biology 2023 Angelos Halaris, John Cook

The glutamatergic system is the primary excitatory pathway within the CNS and is responsible for cognition, memory, learning, emotion, and mood. Because of its significant importance in widespread nervous system function, it is tightly regulated through multiple mechanisms, such as glutamate recycling, microglial interactions, and inflammatory pathways. Imbalance within the glutamatergic system...

DOI: 10.1007/978-981-19-7376-5_21 Full text Esketamine Major depressive disorder Cytokines Glutamatergic system +2

Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.

Progress in Neuro-Psychopharmacology and Biological Psychiatry December 20, 2022 John Cook, Angelos Halaris

Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019. It antagonizes the NMDA receptor providing rapid improvement in symptoms with a complex mechanism of action primarily mediated through glutamatergic activation. Significant barriers exist to widespread use of esketamine including durability of response, particularly in the...

DOI: 10.1016/j.pnpbp.2022.110603 Full text Esketamine Major depressive disorder Dopamine N-methyl-d-aspartate +1